Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IRD | S-3 | bearish | 5/10 | Opus Genetics filed an S-3 registration statement to register up to 2,678,570 shares of common stock for resale by selli | Jun 5, 2026 |
| NCEL | 6-K | neutral | 4/10 | NewcelX Ltd. filed a 6-K furnishing the notice of meeting and proxy card for its Annual General Shareholders' Meeting sc | Jun 5, 2026 |
| XENE | 144 | neutral | 2/10 | Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued | Jun 5, 2026 |
| ELVN | 144 | neutral | 2/10 | Board member Lori Anne Kunkel filed a Form 144 notice of intent to sell 20,000 shares of Enliven Therapeutics (ELVN), wi | Jun 5, 2026 |
| PBMWW | 6-K | neutral | 2/10 | Psyence Biomedical filed an amended equity incentive plan (6-K) to correct a typographical error in Section 4(b) of its | Jun 5, 2026 |
| UNCY | S-3 | bearish | 6/10 | Unicycive Therapeutics filed a universal shelf registration statement on Form S-3 to register up to $150 million in secu | Jun 5, 2026 |
| INSM | CLUSTER | neutral | 2/10 | Five C-suite insiders at INSMED Inc, including the CEO and CFO, collectively sold $1.75M in open-market sales over a 7-d | Jun 5, 2026 |
| INSM | CLUSTER | neutral | 2/10 | Three top INSM insiders, CEO, CFO, and CMO, collectively sold $1.29M in open-market sales over a 7-day window. The total | Jun 5, 2026 |
| HRMY | 144 | neutral | 3/10 | Former officer Sandip Kapadia filed a Form 144 notice of intent to sell 2,101 shares of Harmony Biosciences (HRMY) with | Jun 5, 2026 |
| GRCE | 8-K | neutral | 2/10 | Grace Therapeutics filed an 8-K announcing the departure of Carrie DAndrea as VP of Clinical Operations effective June 5 | Jun 5, 2026 |
| LFCR | 8-K | neutral | 3/10 | Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026 | Jun 5, 2026 |
| QUCY | 8-K | neutral | 3/10 | Quantum Cyber N.V. terminated its at-the-market (ATM) issuance sales agreement with Maxim Group LLC, effective June 7, 2 | Jun 5, 2026 |
| JBIO | PRESS-RELEASE | bearish | 6/10 | Jade Biosciences closed a public offering of 11.5M shares at $15.00/share, raising $172.5M in gross proceeds. The procee | Jun 5, 2026 |
| ELAB | 8-K | neutral | 4/10 | PMGC Holdings Inc. (ELAB), through its wholly owned subsidiary NorthStrive Defense Tech LLC, entered into a binding term | Jun 5, 2026 |
| DBVTF | 8-K | neutral | 2/10 | DBV Technologies granted CEO Daniel Tass 4,060,000 performance share units (PSUs) tied to FDA approval of Viaskin Peanut | Jun 5, 2026 |
| LGVN | 8-K | neutral | 4/10 | CFO Lisa Locklear is stepping down effective July 10, 2026, with controller Marie Washburn expected to be elevated into | Jun 5, 2026 |
| VNRX | 424B5 | bearish | 6/10 | VolitionRx filed a preliminary prospectus supplement for a best-efforts unit offering of common stock, pre-funded warran | Jun 5, 2026 |
| CRBU | DEFA14A | neutral | 2/10 | Caribou Biosciences filed a DEFA14A urging stockholders to vote ahead of the June 17, 2026 annual meeting. The board rec | Jun 5, 2026 |
| ASMB | 8-K | neutral | 2/10 | Assembly Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders approved an increase in shares res | Jun 5, 2026 |
| ANAB | 144 | bearish | 5/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 20,000 common share | Jun 5, 2026 |
| ABCL | 8-K | neutral | 2/10 | AbCellera appointed Dr. Victor Sandor as an independent director on June 1, 2026. Dr. Sandor is a seasoned medical oncol | Jun 5, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K reporting the allotment of 12,100 equity shares upon exercise of stock options under exi | Jun 5, 2026 |
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's d | Jun 5, 2026 |
| NONOF | 6-K | bullish | 7/10 | Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for We | Jun 5, 2026 |
| ANAB | 144 | bearish | 5/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 10,000 shares of common stock, valued | Jun 5, 2026 |
| ACRV | DEFA14A | neutral | 3/10 | Acrivon Therapeutics filed a DEFA14A supplementing its definitive proxy for the June 17, 2026 Annual Meeting, adding a n | Jun 5, 2026 |
| TKPHF | 6-K | bearish | 6/10 | Takeda discloses that a May 18, 2026 jury verdict in the AMITIZA antitrust litigation constitutes an adjusting subsequen | Jun 5, 2026 |
| RNAC | 8-K | bullish | 7/10 | Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an i | Jun 5, 2026 |
| GNPX | 8-K | neutral | 3/10 | Genprex announced that its research collaborators' abstract was published at the 2026 ASCO Annual Meeting, detailing pos | Jun 5, 2026 |
| KLRA | 8-K | neutral | 5/10 | Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9M, widening from $18.0M in Q1 2025, driv | Jun 5, 2026 |